HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Return
11.46%
This Quarter Return
+15.38%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$2.47B
AUM Growth
-$1.39M
(-0.06%)
Cap. Flow
-$200M
Cap. Flow
% of AUM
-8.1%
Top 10 Holdings %
Top 10 Hldgs %
46.45%
Holding
67
New
25
Increased
7
Reduced
17
Closed
14
Top Buys
| 1 |
Maravai LifeSciences
MRVI
|
$87.9M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
$81.7M |
| 3 |
Hologic
HOLX
|
$74.1M |
| 4 |
McKesson
MCK
|
$73.5M |
| 5 |
Bristol-Myers Squibb
BMY
|
$72.7M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$118M |
| 2 |
Zimmer Biomet
ZBH
|
$116M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$107M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
$99.5M |
| 5 |
Medtronic
MDT
|
$93.5M |
Sector Composition
| 1 | Healthcare | 96.62% |
| 2 | Real Estate | 3.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ventas
VTR
$30.8B
| $32.3M | 1.25% |
+658,350
| New | +$32.3M |
|
27
Edwards Lifesciences
EW
$47.6B
| $29.3M | 1.13% |
321,200
+97,340
| +43% | +$8.88M |
|
|
CTLT
28
DELISTED
CATALENT, INC.
CTLT
| $28.1M | 1.08% |
+270,250
| New | +$28.1M |
|
29
Omega Healthcare
OHI
$12.6B
| $28M | 1.08% |
+770,910
| New | +$28M |
|
|
NVRO
30
DELISTED
NEVRO CORP.
NVRO
| $27M | 1.04% |
156,046
-574,931
| -79% | -$99.5M |
|
31
Charles River Laboratories
CRL
$8.01B
| $26.9M | 1.04% |
107,800
-134,430
| -55% | -$33.6M |
|
32
Syndax Pharmaceuticals
SNDX
$1.39B
| $23.8M | 0.92% |
1,070,550
+1,038,350
| +3,225% | +$23.1M |
|
33
Welltower
WELL
$112B
| $23.1M | 0.89% |
+357,120
| New | +$23.1M |
|
34
Neurocrine Biosciences
NBIX
$13.9B
| $21.7M | 0.84% |
226,460
-700,610
| -76% | -$67.2M |
|
35
BioMarin Pharmaceuticals
BMRN
$10.9B
| $19.5M | 0.75% |
222,210
+207,610
| +1,422% | +$18.2M |
|
36
Curis
CRIS
$21M
| $19.4M | 0.75% |
+118,719
| New | +$19.4M |
|
37
Tenet Healthcare
THC
$17B
| $17.2M | 0.66% |
431,441
-683,539
| -61% | -$27.3M |
|
38
CONMED
CNMD
$1.69B
| $11.2M | 0.43% |
+100,000
| New | +$11.2M |
|
|
ALXN
39
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $9.58M | 0.37% |
+61,330
| New | +$9.58M |
|
|
DCPH
40
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.95M | 0.31% |
+139,210
| New | +$7.95M |
|
41
Teleflex
TFX
$5.69B
| $5.41M | 0.21% |
13,150
-152,010
| -92% | -$62.6M |
|
42
Certara
CERT
$1.69B
| $5.06M | 0.2% |
+150,000
| New | +$5.06M |
|
43
Biogen
BIIB
$20.5B
| $2.34M | 0.09% |
+9,560
| New | +$2.34M |
|
|
AMRN
44
Amarin Corp
AMRN
$310M
| $1.92M | 0.07% |
+19,638
| New | +$1.92M |
|
45
Cigna
CI
$80.9B
| $1.77M | 0.07% |
+8,502
| New | +$1.77M |
|
|
ITCI
46
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.75M | 0.07% |
+55,150
| New | +$1.75M |
|
47
Incyte
INCY
$16.7B
| $1.7M | 0.07% |
19,530
-3,050
| -14% | -$265K |
|
|
FPRX
48
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.48M | 0.06% |
+86,930
| New | +$1.48M |
|
49
Anika Therapeutics
ANIK
$131M
| $920K | 0.04% |
+20,320
| New | +$920K |
|
50
Align Technology
ALGN
$9.77B
| – | – |
-14,680
| Closed | -$4.81M |
|